What is the current clinical evidence for tandem CAR T-cell therapies in R/R DLBCL?

The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.